Efficacy Versus Separates

Enstilar® is more effective than its individual active components in achieving treatment success at week 41

Treatment success according to PGA was defined as clear or almost clear from baseline for patients with moderate/severe disease and clear
from baseline for those with mild disease.1,2

The proportion of patients achieving clear or almost clear skin† at week 4 on trunk and limbs:1

Graph Enstilar vs individual components

Study design:

A randomised, double-blind, multicentre, three-arm, phase II, 4 week trial in adult patients with plaque psoriasis, treatment success* at 4 weeks.
†Absolute reduction in mean mPASI of 2.8 at week 1 and 5.4 at week 4.2

How does a topical combination treat both elements of plaque psoriasis?

Dr Stuart Wolfman, Dr George Moncrieff and Dr Angelika Razzaque

View more videos from experts in dermatology

Why wait?

Optimise your patient’s
treatment and advance them
to Enstilar®

Return to the efficacy overview
See the difference in patients
CI: confidence interval
OR: odds ratio
PASI: Psoriasis Area Severity Index.
PGA: physician’s global assessment.
  1. Lebwohl M et al. J Clin Aesthet Dermatol 2016;9(2):34–41.
  2. Leonardi C et al. J Drugs Dermatol 2015;14(12):1468–1477.
MAT-26551 July 2019

Keep in touch with LEO Pharma

Latest product information, consultation tools, hot topics in dermatology and congress updates.  Be the first to know with LEO Pharma. Sign up

MAT-29941 November 2019

Holler Box